Prostate Cancer
Conditions
Brief summary
The main rationale underlying this study is that prostate cancer clinical trials are lacking representation from racial and ethnic minority groups. Study proposal aims to target barriers at the participant, investigator, and health system level through specific interventions to increase the percentage of participants from these backgrounds on cancer clinical trials.
Detailed description
Primary Objectives: The study objective is to increase the number of participants on prostate cancer clinical trials at LBJ. Investigators will complete several objectives: * To design a culturally tailored video highlighting participant narratives and determine its impact on participants' decision-making pertaining to joining a clinical trial * To conduct educational sessions with frontline oncology providers * To coordinate participant care through utilization of a nurse navigator * To evaluate the effectiveness of this multi-pronged intervention to increase enrollment onto two prostate cancer clinical trials and compare enrollment and one-year retention rates before and after the intervention
Interventions
OTHERVideo
Participants will watch a short video in clinic. Participants will complete the two validated scales before and after viewing the video.
Sponsors
M.D. Anderson Cancer Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
These criteria include diagnosed prostate cancer patients receiving care at LBJ Hospital who Are eligible for an open prostate cancer clinical trial at LBJ Hospital during the study period Can provide informed consent.
Exclusion criteria
These criteria include prostate cancer patients receiving care at LBJ who are unable to participate due to a serious psychological or cognitive condition or have a medical condition that prevents participation in the trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and Adverse Events (AEs) | Through study completion; an average of 1 year | Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 |
Countries
United States
Contacts
CONTACTDebanjan Pain, MD
PRINCIPAL_INVESTIGATORDebanjan Pain, MD
M.D. Anderson Cancer Center
Outcome results
None listed